Dr. Lamanna Discusses Lymphocytosis Following CLL Treatment

Nicole Lamanna, MD
Published: Friday, Oct 03, 2014

Nicole Lamanna, MD, clinical professor of medicine, Columbia University Medical Center, discusses lymphocytosis following treatment with new oral CLL agents.

Lamanna says regular IV chemotherapy would knock down patients' blood count. Once a patient is treated with new oral agents, such as ibrutinib, the lymph nodes shrink, causing the blood count to rise. This caused some alarm in early clinical trials because researchers thought patients were progressing, Lamanna says.

Lamanna says over time, usually in a matter of months, the lymphocytosis resolves and gets better.
Nicole Lamanna, MD, clinical professor of medicine, Columbia University Medical Center, discusses lymphocytosis following treatment with new oral CLL agents.

Lamanna says regular IV chemotherapy would knock down patients' blood count. Once a patient is treated with new oral agents, such as ibrutinib, the lymph nodes shrink, causing the blood count to rise. This caused some alarm in early clinical trials because researchers thought patients were progressing, Lamanna says.

Lamanna says over time, usually in a matter of months, the lymphocytosis resolves and gets better.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x